India Ratings and Research on Wednesday maintained a neutral outlook on Indian states’ finances for FY27, projecting the ...
Prices of weight loss drug Semaglutide to drop by over 65% in India post March patent expiry: Ind-Ra
Monthly treatment costs for popular weight-loss drugs like Ozempic and Wegovy are expected to plummet from ₹12,000 to nearly ₹3,000 as the semaglutide patent expires in March 2026.
India Ratings and Research has revised its outlook on the retail jewellery sector to neutral for FY27, signalling a more balanced view after recent growth. The agency expects FY26 to deliver solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results